About Index Trending news
Analyze
Pricing
Critical Outcome Technologies

Critical Outcome Technologies

Critical Outcome Technologies

Multiple clinical trials planned for COTI-2, our p53-dependent, potential breakthrough treatment for many cancers. | Listed on the TSX Venture Exchange as COT.

Elsewhere

Alexa global traffic share

Twitter followers

25 Sep 2014
$45,758
Venture capital
01 Aug 2014
$1,300,000
Post-IPO equity
06 May 2014
$285,000
Undisclosed funding